Citigroup
RNAZ icon

Citigroup’s TransCode Therapeutics RNAZ Stock Holding History

Citigroup’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,586
Closed -$17K – 6402
2025
Q3 		$17K Buy
+1,586
New +$16.5K ﹤0.01% 4872

Other funds holding RNAZ

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citigroup's RNAZ Position: Q4 2025 in Review

Citigroup sold out of TransCode Therapeutics (RNAZ) in Q4 2025, closing a stake of 1,586 shares — an estimated $17K sold.

Citigroup first reported a position in RNAZ in Q3 2025 and held it in 1 quarter. The position peaked at $17K in Q3 2025. 6 funds tracked by Wall St. Rank hold RNAZ as of Q4 2025.

  • Citigroup reported no remaining TransCode Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 1,586 TransCode Therapeutics shares in Q4 2025, an estimated $17K.
  • Citigroup first reported a position in TransCode Therapeutics in Q3 2025 and held it in 1 quarter.
  • Citigroup's TransCode Therapeutics position peaked at $17K in Q3 2025.
  • 6 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.